VTRS Viatris Inc. - Common Stock

NASDAQ · Pharmaceuticals · Ver en SEC EDGAR ↗
$16,50
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 6, 2026

Acerca de Viatris Inc. - Common Stock Descripción general de la empresa de Wikipedia

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

Leer más

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.

Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies.

History

On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. At that time, Michael Goettler became chief executive officer. Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS. In December 2020, the company announced a cost-reducing restructuring plan that would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world.

In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. The transaction was completed in November 2022. In November 2022, the business agreed to acquire Oyster Point Pharma and Famy Life Sciences for an aggregate of $700–750 million to create an ophthalmology division. The acquisitions closed in January 2023.

In 2022 and 2024, Viatris was recognized by Forbes as one of the world's best employers and by Newsweek as one of America's most responsible companies. On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, and one of the 25 best companies offering career development in Ireland. In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.

In late December 2024, Viatris disclosed that the U.S. FDA had issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the warning letter is lifted, while four products were conditionally exempted due to shortages. The violations cited by the FDA included subpar quality control and improper management of manufacturing defect. In response, the company announced that it has taken corrective and preventative actions.

Predecessors

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Products

The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients. Viatris products cover therapeutic areas including cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.

The following products have been newly launched or received regulatory approvals since Viatris was established include:

Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.

Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.

GA Depot (long-acting version of glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.

Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.

Ryzumvi (phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.

Partnerships

Following the formation of Viatris, the company became a member of the Biosimilars Forum, a trade organization that advocates for greater biosimilar usage. Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world.

In December 2020, the company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic. In April 2021, the company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%.

In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

VTRS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

Precio
$16.50
Capitalización Bursátil
P/E (TTM)
-4.2
BPA (TTM)
$-3.00
Ingresos (TTM)
$14.30B
Rendimiento div.
ROE
-23.2%
Deuda/Capital
1.0
Rango 52S
$9 – $18

VTRS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

Ingresos y Beneficio Neto $14.30B
8-point trend, +25.1%
2018-12-31 2025-12-31
BPA $-3.00
8-point trend, -541.2%
2018-12-31 2025-12-31
Flujo de caja libre $1.94B
2025-12-31 2025-12-31
Márgenes -24.6%
2025-12-31 2025-12-31

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares
P/E (TTM)
5-point trend, +67.8%
-4.2
32.1

Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares
Gross Margin (Margen Bruto)
35.1%
71.8%
Operating Margin (Margen Operativo)
-18.6%
Net Profit Margin (Margen de Beneficio Neto)
-24.6%
13.0%
ROA
-8.9%
6.4%
ROE
-23.2%
15.1%
ROIC
-8.8%

Salud financiera Deuda, liquidez, solvencia — solidez del balance general

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
1.0
Current Ratio (Ratio corriente)
1.4
1.6
Quick Ratio (Ratio Rápido)
0.6

Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares
Revenue YoY (Ingresos interanuales)
5-point trend, -20.1%
-3.0%
Revenue CAGR 3Y (Ingresos CAGR 3A)
5-point trend, -20.1%
-4.2%
Revenue CAGR 5Y (Ingresos CAGR 5A)
5-point trend, -20.1%
3.7%
EPS YoY (EPS interanual)
5-point trend, -185.7%
-97.1%
Net Income YoY (Beneficio Neto interanual)
5-point trend, -177.0%
-97.4%

Métricas por acción BPA, valor contable por acción, flujo de caja por acción, dividendo por acción

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares
EPS (Diluted) (BPA (Diluido))
5-point trend, -185.7%
$-3.00

Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar

Métrica
Tendencia a 5 años
VTRS
Mediana de Pares

Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años

Rendimiento por Dividendo
Ratio de Pago
CAGR de Dividendos a 5 años
Fecha ex-dividendoMonto
22 de mayo de 2026$0,1200
9 de marzo de 2026$0,1200
24 de noviembre de 2025$0,1200
22 de agosto de 2025$0,1200
23 de mayo de 2025$0,1200
10 de marzo de 2025$0,1200
22 de noviembre de 2024$0,1200
23 de agosto de 2024$0,1200
23 de mayo de 2024$0,1200
8 de marzo de 2024$0,1200
22 de noviembre de 2023$0,1200
23 de agosto de 2023$0,1200
23 de mayo de 2023$0,1200
8 de marzo de 2023$0,1200
22 de noviembre de 2022$0,1200
23 de agosto de 2022$0,1200
23 de mayo de 2022$0,1200
23 de febrero de 2022$0,1200
22 de noviembre de 2021$0,1100
23 de agosto de 2021$0,1100

VTRS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

COMPRA 17 analistas
  • Compra fuerte 4 23,5%
  • Compra 7 41,2%
  • Mantener 5 29,4%
  • Venta 1 5,9%
  • Venta fuerte 0 0,0%

Precio objetivo a 12 meses

8 analistas · 2026-08-19
Objetivo mediano $19.00 +15,2%
Objetivo medio $18.50 +12,1%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

Sorpresa Media
0.05%
Período EPS Actual EPS est. Sorpresa
30 de junio de 2026 $0.69 $0.61 0.08%
31 de marzo de 2026 $0.59 $0.51 0.08%
31 de diciembre de 2025 $0.57 $0.54 0.03%
30 de septiembre de 2025 $0.67 $0.63 0.04%
30 de junio de 2025 $0.62 $0.57 0.05%
31 de marzo de 2025 $0.50 $0.50 0.00%

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
VTRS -4.2 -3.0% -24.6% -23.2% 35.1%
MRK 14.5 1.3% 28.1% 36.9%
PFE 18.3 -1.7% 12.4% 8.9%
BMY 15.6 -0.22% 14.6% 40.5%
RPRX 21.7 5.1% 32.4% 8.0%
ZTS $53.46B 20.9 2.3% 28.2% 66.0%
CORT $3.69B 42.4 12.8% 13.1% 15.5%
ELAN $11.25B -48.1 6.2% -4.9% -3.5% 55.0%
AXSM $9.29B -49.6 65.5% -28.7% -227.0%
CRNX $4.45B -9.4 640.7% -6046.2% -43.0%
LLY 46.8 44.7% 31.7% 101.2%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

Estado de resultados 17
Datos anuales de Estado de resultados para VTRS
Métrica Tendencia 20252024202320222021202020192018
Revenue 8-point trend, +25.1% $14.30B $14.74B $15.43B $16.26B $17.89B $11.95B $11.50B $11.43B
Cost of Revenue 8-point trend, +24.9% $9.29B $9.12B $8.99B $9.77B $12.31B $8.15B $7.60B $7.43B
Gross Profit 8-point trend, +25.3% $5.01B $5.62B $6.44B $6.50B $5.58B $3.80B $3.90B $4.00B
R&D Expense 4-point trend, +6.6% · · · · $751M $555M $640M $704M
SG&A Expense 8-point trend, +55.4% $3.79B $4.10B $4.07B $4.18B $4.53B $3.34B $2.56B $2.44B
Operating Expenses 8-point trend, +148.0% $7.68B $5.61B $5.67B $4.88B $5.61B $4.01B $3.18B $3.10B
Operating Income 8-point trend, -394.1% $-2.66B $10M $766M $1.61B $-34M $-211M $716M $906M
Interest Expense 8-point trend, -13.1% $471M $550M $573M $592M $636M $498M $517M $542M
Other Non-op 8-point trend, -717.6% $-531M $-83M $10M $1.79B $6M $-13M $-44M $-65M
Pretax Income 8-point trend, -1328.2% $-3.67B $-623M $203M $2.81B $-664M $-721M $154M $298M
Income Tax 8-point trend, -177.4% $-150M $11M $148M $735M $605M $-51M $138M $-54M
Net Income 8-point trend, -1097.1% $-3.51B $-634M $55M $2.08B $-1.27B $-670M $17M $352M
EPS (Basic) 8-point trend, -534.8% $-3.00 $-0.53 $0.05 $1.71 $-1.05 $-1.11 $0.03 $0.69
EPS (Diluted) 8-point trend, -541.2% $-3.00 $-0.53 $0.05 $1.71 $-1.05 $-1.11 $0.03 $0.68
Shares (Basic) 6-point trend, +133.3% · · 1,200,300,000 1,212,100,000 1,208,800,000 601,200,000 515,700,000 514,500,000
Shares (Diluted) 6-point trend, +133.7% · · 1,206,900,000 1,217,400,000 1,208,800,000 601,200,000 516,500,000 516,500,000
EBITDA $135M · · · · · · ·
Balance general 30
Datos anuales de Balance general para VTRS
Métrica Tendencia 20252024202320222021202020192018
Cash & Equivalents 8-point trend, +240.7% $1.32B $735M $992M $1.26B $701M $844M $476M $388M
Short-term Investments 2-point trend, +45.9% · · · · · $39M $27M ·
Receivables 7-point trend, -0.9% $3.03B $3.22B $3.70B $3.81B $4.27B $4.84B $3.06B ·
Inventory 7-point trend, +49.7% $4.00B $3.85B $3.47B $3.52B $3.98B $5.47B $2.67B ·
Prepaid Expense 7-point trend, +160.2% $1.44B $1.71B $2.03B $1.81B $1.96B $1.71B $552M ·
Other Current Assets 7-point trend, -52.4% $136M $387M $271M $328M $1.47B $1.24B $286M ·
Current Assets 7-point trend, +44.9% $9.79B $9.52B $12.98B $10.64B $10.90B $12.87B $6.76B ·
PP&E (Net) 7-point trend, +21.6% $2.61B $2.67B $2.76B $3.02B $3.19B $3.46B $2.15B ·
PP&E (Gross) 7-point trend, +24.5% $5.13B $4.87B $4.77B $5.08B $5.59B $5.72B $4.12B ·
Accum. Depreciation 7-point trend, +27.7% $2.52B $2.20B $2.01B $2.06B $2.40B $2.26B $1.97B ·
Goodwill 8-point trend, -30.7% $6.75B $9.13B $9.87B $10.43B $12.11B $12.35B $9.59B $9.75B
Intangibles 7-point trend, +29.6% $15.10B $17.07B $19.18B $22.61B $26.13B $29.68B $11.65B ·
Other Non-current Assets 7-point trend, +362.2% $1.87B $2.36B $2.21B $2.40B $1.17B $1.05B $405M ·
Total Assets 7-point trend, +19.0% $37.19B $41.50B $47.69B $50.02B $54.84B $61.55B $31.26B ·
Short-term Debt 4-point trend, +0.00 · · · $0 $1.49B $1.10B $0 ·
Current Liabilities 7-point trend, +27.4% $7.09B $5.78B $7.78B $6.75B $9.88B $10.56B $5.57B ·
Capital Leases 7-point trend, +1.4% $178M $179M $165M $181M $201M $230M $176M ·
Deferred Tax 7-point trend, -45.2% $892M $1.11B $1.74B $2.43B $2.81B $3.12B $1.63B ·
Other Non-current Liabilities 7-point trend, +109.7% $2.01B $1.94B $1.52B $1.76B $1.93B $2.48B $961M ·
Total Liabilities 7-point trend, +16.1% $22.48B $22.87B $27.22B $28.95B $34.35B $38.60B $19.37B ·
Long-term Debt 7-point trend, +13.3% $14.41B $14.05B $18.13B $19.27B $21.59B $24.74B $12.72B ·
Total Debt $14.41B · · · · · · ·
Common Stock 7-point trend, +104.9% $12M $12M $12M $12M $12M $12M $6M ·
Paid-in Capital 7-point trend, +117.5% $18.80B $18.92B $18.81B $18.65B $18.54B $18.44B $8.64B ·
Retained Earnings 7-point trend, -106.4% $-388M $3.42B $4.64B $5.18B $3.69B $5.36B $6.03B ·
Treasury Stock 7-point trend, +0.8% $1.01B $504M $252M $0 $0 $0 $1000M ·
AOCI 7-point trend, -50.6% $-2.71B $-3.21B $-2.75B $-2.76B $-1.74B $-858M $-1.80B ·
Stockholders' Equity 8-point trend, +20.9% $14.71B $18.64B $20.47B $21.07B $20.49B $22.95B $11.88B $12.17B
Liabilities + Equity 7-point trend, +19.0% $37.19B $41.50B $47.69B $50.02B $54.84B $61.55B $31.26B ·
Shares Outstanding · · · · · · 100 ·
Flujo de Efectivo 19
Datos anuales de Flujo de Efectivo para VTRS
Métrica Tendencia 20252024202320222021202020192018
D&A 8-point trend, +32.6% $2.80B $2.89B $2.74B $3.03B $4.51B $2.22B $2.02B $2.11B
Stock-based Comp 8-point trend, +5484.8% $178M $146M $181M $116M $111M $79M $57M $-3M
Deferred Tax 8-point trend, -80.3% $-476M $-768M $-387M $-26M $676M $-213M $-193M $-264M
Amort. of Intangibles 8-point trend, +46.3% $2.35B $2.35B $2.32B $2.50B $2.70B $1.61B $1.58B $1.61B
Restructuring 3-point trend, -51.7% · · · · $50M $50M $105M ·
Other Non-cash $3.33B · · · · · · ·
Operating Cash Flow 8-point trend, -1.1% $2.32B $2.30B $2.90B $3.00B $3.02B $1.23B $1.80B $2.34B
CapEx 8-point trend, +50.3% $379M $326M $377M $406M $457M $243M $213M $252M
Investing Cash Flow 8-point trend, +64.7% $-428M $1.80B $-864M $1.47B $-118M $-301M $-525M $-1.21B
Debt Issued 8-point trend, -100.0% $0 $0 $300.0K $1.88B $1.71B $983M $7M $2.58B
Net Debt Issued $-100.0K · · · · · · ·
Stock Issued 6-point trend, +2600000.00 $3M $2M $3M $3M $0 $0 · ·
Stock Repurchased 8-point trend, +15.9% $500M $250M $250M $0 $0 $0 $0 $432M
Net Stock Activity $-498M · · · · · · ·
Financing Cash Flow 8-point trend, -18.6% $-1.29B $-4.33B $-2.30B $-3.88B $-3.01B $-606M $-1.17B $-1.09B
Net Change in Cash 8-point trend, +3054.1% $612M $-258M $-269M $556M $-144M $359M $102M $19M
Taxes Paid $445M · · · · · · ·
Free Cash Flow $1.94B · · · · · · ·
Levered FCF $1.49B · · · · · · ·
Rentabilidad 8
Datos anuales de Rentabilidad para VTRS
Métrica Tendencia 20252024202320222021202020192018
Gross Margin 35.1% · · · · · · ·
Operating Margin -18.6% · · · · · · ·
Net Margin -24.6% · · · · · · ·
Pretax Margin -25.6% · · · · · · ·
EBITDA Margin 0.95% · · · · · · ·
ROA -8.9% · · · · · · ·
ROE -23.2% · · · · · · ·
ROIC -8.8% · · · · · · ·
Liquidez y Solvencia 5
Datos anuales de Liquidez y Solvencia para VTRS
Métrica Tendencia 20252024202320222021202020192018
Current Ratio 1.4 · · · · · · ·
Quick Ratio 0.6 · · · · · · ·
Debt / Equity 1.0 · · · · · · ·
LT Debt / Equity 0.8 · · · · · · ·
Interest Coverage -5.7 · · · · · · ·
Eficiencia 3
Datos anuales de Eficiencia para VTRS
Métrica Tendencia 20252024202320222021202020192018
Asset Turnover 0.4 · · · · · · ·
Inventory Turnover 2.4 · · · · · · ·
Receivables Turnover 4.6 · · · · · · ·
Por Acción 3
Datos anuales de Por Acción para VTRS
Métrica Tendencia 20252024202320222021202020192018
Book Value / Share · · · · · · $0.00 ·
Dividend Paid / Share 5-point trend, +45.5% $0 $0 $0 $0 $0 · · ·
EPS (TTM) 7-point trend, -10100.0% $-3.00 $-0.53 $0.05 $1.71 $-1.05 $-1.11 $0.03 ·
Tasas de Crecimiento 5
Datos anuales de Tasas de Crecimiento para VTRS
Métrica Tendencia 20252024202320222021202020192018
Revenue YoY 5-point trend, -106.0% -3.0% -4.5% -5.1% -9.1% 49.7% · · ·
Revenue CAGR 3Y 3-point trend, -147.2% -4.2% -6.2% 8.9% · · · · ·
Revenue CAGR 5Y 3.7% · · · · · · ·
EPS YoY · · -97.1% · · · · ·
Net Income YoY · · -97.4% · · · · ·
Valoración (TTM) 6
Datos anuales de Valoración (TTM) para VTRS
Métrica Tendencia 20252024202320222021202020192018
Revenue TTM 7-point trend, +24.3% $14.30B $14.74B $15.43B $16.26B $17.89B $11.95B $11.50B ·
Net Income TTM 7-point trend, -21022.0% $-3.51B $-634M $55M $2.08B $-1.27B $-670M $17M ·
Market Cap · · · · · · $2.0K ·
P/E 7-point trend, -100.6% -4.2 -23.5 216.6 6.5 -12.9 -16.9 670.0 ·
P/S · · · · · · 0.0 ·
Earnings Yield 7-point trend, -16166.7% -24.1% -4.3% 0.46% 15.4% -7.8% -5.9% 0.15% ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

Estado de resultados
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $14.30B$14.74B$15.43B$16.26B$17.89B
Margen Bruto % 35.1%
Margen Operativo % -18.6%
Beneficio neto $-3.51B$-634M$55M$2.08B$-1.27B
EPS Diluido $-3.00$-0.53$0.05$1.71$-1.05
Balance general
2025-12-312024-12-312023-12-312022-12-312021-12-31
Deuda / Patrimonio 1.0
Ratio corriente 1.4
Ratio Rápido 0.6
Flujo de Efectivo
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flujo de caja libre $1.94B

Últimas noticias Noticias recientes que mencionan a esta empresa

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

📊

Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Propietarios institucionales (13F) 1 132 declarantes · $12.6B total · A fecha de 30 de junio de 2026

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
113 (-35 vs trimestre anterior) 87 (0 vs trimestre anterior) 352 (+15 vs trimestre anterior) 311 (+5 vs trimestre anterior) +245.4M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
VANGUARD GROUP INC $1 590 154 649 127 723 265 12,66% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $1 207 625 391 76 046 939 9,61% Acciones
Davis Selected Advisers $1 194 789 797 75 232 254 9,51% Acciones
FMR LLC $992 936 353 62 527 478 7,91% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $861 999 430 54 282 080 6,86% Acciones
STATE STREET CORP $842 743 041 53 069 461 6,71% Acciones
Rubric Capital Management LP $542 599 639 34 168 743 4,32% Acciones
GEODE CAPITAL MANAGEMENT, LLC $458 542 313 28 931 625 3,65% Acciones
DIMENSIONAL FUND ADVISORS LP $425 986 168 26 825 324 3,39% Acciones
DEERFIELD MANAGEMENT COMPANY, L.P. $320 873 980 20 206 170 2,55% Acciones
AMERIPRISE FINANCIAL INC $294 863 935 18 568 141 2,35% Acciones
GLENVIEW CAPITAL MANAGEMENT, LLC $156 853 255 9 877 409 1,25% Acciones
GOLDMAN SACHS GROUP INC $138 959 750 8 750 614 1,11% Acciones
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $132 934 942 8 371 218 1,06% Acciones
Callodine Capital Management, LP $127 051 783 8 000 742 1,01% Acciones
VANGUARD FIDUCIARY TRUST CO $103 910 383 6 543 475 0,83% Acciones
Qube Research & Technologies Ltd $98 141 941 6 180 223 0,78% Acciones
Nantahala Capital Management, LLC $79 400 000 5 000 000 0,63% Opción de compra
Assenagon Asset Management S.A. $79 225 415 4 989 006 0,63% Acciones
AMERICAN CENTURY COMPANIES INC $73 760 258 4 644 851 0,59% Acciones
FRANKLIN RESOURCES INC $73 433 026 4 624 246 0,58% Acciones
Gotham Asset Management, LLC $69 469 966 4 374 683 0,55% Acciones
Brandywine Global Investment Management, LLC $67 528 501 5 423 976 0,54% Acciones
NORGES BANK $60 705 175 3 822 744 0,48% Acciones
LAKEWOOD CAPITAL MANAGEMENT, LP $59 326 092 3 735 900 0,47% Acciones
BlackRock, Inc. $50 770 853 3 197 157 0,40% Acciones
RHUMBLINE ADVISERS $45 614 656 2 872 464 0,36% Acciones
Vanguard Global Advisers, LLC $42 862 486 2 699 149 0,34% Acciones
VICTORY CAPITAL MANAGEMENT INC $42 610 407 2 683 275 0,34% Acciones
FLPUTNAM INVESTMENT MANAGEMENT CO $42 249 391 2 660 541 0,34% Acciones
California Public Employees Retirement System $40 629 123 2 558 509 0,32% Acciones
ARGENT CAPITAL MANAGEMENT LLC $40 499 641 2 550 355 0,32% Acciones
DME Capital Management, LP $39 761 614 2 503 880 0,32% Acciones
Pictet Asset Management Holding SA $39 481 647 2 437 987 0,31% Acciones
ENVESTNET ASSET MANAGEMENT INC $37 396 986 2 354 974 0,30% Acciones
Swiss National Bank $37 102 064 2 336 402 0,30% Acciones
MANUFACTURERS LIFE INSURANCE COMPANY, THE $34 474 638 2 170 947 0,27% Acciones
FIL Ltd $33 643 336 2 118 598 0,27% Acciones
Robeco Institutional Asset Management B.V. $33 037 834 2 080 468 0,26% Acciones
BARCLAYS PLC $32 535 722 2 048 849 0,26% Acciones
Allianz Asset Management GmbH $32 188 236 2 026 967 0,26% Acciones
Legal & General Group Plc $31 446 226 1 980 241 0,25% Acciones
BANK OF NOVA SCOTIA $28 130 467 1 771 440 0,22% Acciones
SEI INVESTMENTS CO $28 129 290 1 771 366 0,22% Acciones
BANK OF AMERICA CORP /DE/ $28 053 767 1 766 610 0,22% Acciones
BNP PARIBAS FINANCIAL MARKETS $27 953 373 1 760 288 0,22% Acciones
TORONTO DOMINION BANK $27 612 303 1 738 810 0,22% Acciones
Invenomic Capital Management LP $27 611 985 1 738 790 0,22% Acciones
Bridgewater Associates, LP $26 969 655 1 698 341 0,21% Acciones
WEDGE CAPITAL MANAGEMENT L L P/NC $26 265 777 1 944 173 0,21% Acciones
RAYMOND JAMES FINANCIAL INC $24 676 772 1 553 953 0,20% Acciones
Camber Capital Management LP $24 557 500 2 750 000 0,20% Acciones
Arnhold LLC $23 200 267 1 460 974 0,18% Acciones
MANNING & NAPIER ADVISORS LLC $23 136 612 1 425 546 0,18% Acciones
Mitsubishi UFJ Asset Management Co., Ltd. $22 918 445 1 443 227 0,18% Acciones
MOORE CAPITAL MANAGEMENT, LP $22 718 786 1 430 654 0,18% Acciones
Quantinno Capital Management LP $21 730 727 1 368 433 0,17% Acciones
Quaker Capital Investments, LLC $21 567 486 1 358 154 0,17% Acciones
MOORE CAPITAL MANAGEMENT, LP $21 126 752 1 330 400 0,17% Opción de venta
STATE OF WISCONSIN INVESTMENT BOARD $20 950 929 1 319 328 0,17% Acciones
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $20 773 000 1 308 106 0,17% Acciones
Man Group plc $20 719 636 1 304 763 0,16% Acciones
PRINCIPAL FINANCIAL GROUP INC $19 978 215 1 258 074 0,16% Acciones
Caption Management, LLC $19 850 000 1 250 000 0,16% Opción de venta
Monaco Asset Management SAM $19 287 419 1 214 573 0,15% Acciones
UBS Group AG $18 638 340 1 173 699 0,15% Acciones
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $18 213 709 1 348 165 0,15% Acciones
ARCADIA INVESTMENT MANAGEMENT CORP/MI $17 959 195 1 329 326 0,14% Acciones
VANGUARD ASSET MANAGEMENT, Ltd $17 915 228 1 128 163 0,14% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $17 890 408 1 126 600 0,14% Opción de compra
HIGHLAND PEAK CAPITAL, LLC $17 495 488 1 101 731 0,14% Acciones
THOMPSON INVESTMENT MANAGEMENT, INC. $17 330 906 1 091 367 0,14% Acciones
ALLIANCEBERNSTEIN L.P. $16 660 991 1 233 234 0,13% Acciones
Bastion Asset Management Inc. $16 191 713 1 052 647 0,13% Acciones
QSM Asset Management Ltd $15 898 267 996 132 0,13% Acciones
TD Asset Management Inc $15 844 127 997 741 0,13% Acciones
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $15 495 783 975 805 0,12% Acciones
Sio Capital Management, LLC $15 154 268 954 299 0,12% Acciones
PRUDENTIAL FINANCIAL INC $13 466 796 848 035 0,11% Acciones
Illinois Municipal Retirement Fund $13 448 693 846 895 0,11% Acciones
ADAGE CAPITAL PARTNERS GP, L.L.C. $13 398 528 843 736 0,11% Acciones
LEVIN CAPITAL STRATEGIES, L.P. $13 365 809 841 676 0,11% Acciones
Woodline Partners LP $12 753 911 803 143 0,10% Acciones
HSBC HOLDINGS PLC $12 656 884 797 033 0,10% Acciones
EDMOND DE ROTHSCHILD HOLDING S.A. $12 545 248 790 003 0,10% Acciones
CONTINENTAL ADVISORS LLC $12 430 070 782 750 0,10% Acciones
LOS ANGELES CAPITAL MANAGEMENT LLC $11 932 326 751 406 0,09% Acciones
Miller Value Partners, LLC $11 642 644 733 164 0,09% Acciones
ALGERT GLOBAL LLC $11 559 052 727 900 0,09% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $11 509 824 724 800 0,09% Opción de venta
VestGen Advisors, LLC $11 228 726 707 099 0,09% Acciones
Atom Investors LP $11 206 246 705 683 0,09% Acciones
STOREBRAND ASSET MANAGEMENT AS $10 891 425 685 858 0,09% Acciones
APG Asset Management N.V. $10 865 473 782 273 0,09% Acciones
MARSHALL WACE, LLP $10 826 793 681 788 0,09% Acciones
LPL Financial LLC $10 767 536 678 057 0,09% Acciones
Poehling Capital Management, INC. $10 675 322 672 250 0,08% Acciones
Zurcher Kantonalbank (Zurich Cantonalbank) $10 620 957 668 826 0,08% Acciones
CITADEL ADVISORS LLC $10 496 680 661 000 0,08% Opción de compra
Sound Income Strategies, LLC $10 242 156 644 972 0,08% Acciones

Informantes de la empresa 31 insiders · 14 directivos · 20 consejeros

Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Scott Andrew Smith Chief Executive Officer 6 de marzo de 2026 A 1 329 326 0 0 $0
Michael Goettler Chief Executive Officer 4 de marzo de 2023 M 321 653 0 0 $0
Campbell Paul Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller 25 de junio de 2026 S 316 212 0 2 $-1 093 257
Theodora Mistras Chief Financial Officer 6 de marzo de 2026 A 70 645 0 0 $0
Sanjeev Narula Chief Financial Officer 4 de marzo de 2023 M 73 877 0 0 $0
Anthony Mauro President, Developed Markets 13 de marzo de 2024 S 243 044 0 0 $0
Xiangyang (Sean) Ni President, Greater China 4 de marzo de 2024 A 90 804 0 0 $0
Andrew Cuneo President, JANZ (Japan, Australia and New Zealand) and Emerging Markets 4 de marzo de 2024 A 60 055 0 0 $0
Menassie Taddese President, Emerging Markets 27 de mayo de 2022 S 0 0 0 $0
Andrew Enrietti Chief Administrative and Transformation Officer 15 de agosto de 2026 M 234 444 0 0 $0
Corinne Le Goff Chief Commercial Officer 15 de abril de 2026 M 107 135 0 1 $-72 078
Matthew Joseph Maletta Chief Legal Officer 6 de marzo de 2026 A 0 0 $0
Brian Roman Chief Legal Officer 6 de marzo de 2025 A 193 916 0 0 $0
Robert J Coury Executive Chairman 4 de marzo de 2023 M 1 174 515 0 0 $0
Leo Frans Groothuis Consejero 30 de junio de 2026 A 63 437 0 0 $0
David S Simmons Consejero 30 de junio de 2026 A 23 344 2 0 $5 202
Richard A Mark Consejero 6 de marzo de 2026 A 116 145 0 0 $0
Coelho Rogerio Vivaldi Consejero 6 de marzo de 2026 A 46 526 0 0 $0
Michael Severino Consejero 6 de marzo de 2026 A 26 031 0 0 $0
Dillon Joellen Lyons Consejero 6 de marzo de 2026 A 102 526 0 0 $0
Mark W Parrish Consejero 6 de marzo de 2026 A 165 230 0 0 $0
Elisha W Finney Consejero 6 de marzo de 2026 A 62 667 0 0 $0
Frank A Damelio Consejero 6 de marzo de 2026 A 26 031 0 0 $0
Don W Cornwell Consejero 6 de marzo de 2026 A 112 044 0 0 $0
Melina E Higgins Consejero 6 de marzo de 2026 A 146 048 0 0 $0
James M Kilts Consejero 6 de marzo de 2026 A 161 257 0 0 $0
Rajiv Malik Consejero 6 de marzo de 2025 A 1 068 262 0 0 $0
Harry Korman Consejero 6 de marzo de 2025 A 113 937 0 0 $0
Mohr Pauline Van Der Meer Consejero 4 de marzo de 2023 M 40 245 0 0 $0
Ian C Read Consejero 21 de marzo de 2022 M 14 497 0 0 $0
Neil F Dimick Consejero 21 de marzo de 2022 M 75 200 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Propiedad de ETFs Mantenido por 159 ETFs

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
DUSA · Davis Fundamental ETF Trust 4,97% 3 855 281 NS 30 de abril de 2026 N-PORT
IHE · iShares Trust 4,18% 4 159 839 SH 8 de agosto de 2026 Diario
ADPV · Series Portfolios Trust 4,11% 471 687 NS 30 de abril de 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 4,01% 1 522 109 NS 30 de abril de 2026 N-PORT
LBAY · Tidal Trust I 3,80% 41 162 NS 31 de mayo de 2026 N-PORT
PJP · Invesco Exchange-Traded Fund Trust 2,57% 791 598 SH 8 de agosto de 2026 Diario
LYLD · Cambria ETF Trust 2,12% 8 544 NS 30 de abril de 2026 N-PORT
SPDV · ETF Series Solutions 2,08% 125 516 NS 30 de abril de 2026 N-PORT
ABIG · EA Series Trust 1,97% 67 399 NS 29 de mayo de 2026 N-PORT
PTH · Invesco Exchange-Traded Fund Trust 1,64% 246 267 SH 8 de agosto de 2026 Diario
RSPH · Invesco Exchange-Traded Fund Trust 1,58% 751 666 SH 8 de agosto de 2026 Diario
PILL · Direxion Shares ETF Trust 1,43% 12 352 NS 30 de abril de 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 1,30% 63 374 SH 8 de agosto de 2026 Diario
RPV · Invesco Exchange-Traded Fund Trust 1,14% 1 183 250 SH 8 de agosto de 2026 Diario
SYLD · Cambria ETF Trust 1,03% 662 665 NS 30 de abril de 2026 N-PORT
BIB · ProShares Trust 0,94% 42 565 NS 31 de mayo de 2026 N-PORT
CZA · Invesco Exchange-Traded Fund Trust 0,89% 104 432 SH 8 de agosto de 2026 Diario
SPVM · Invesco Exchange-Traded Fund Trust 0,71% 56 727 SH 8 de agosto de 2026 Diario
DFAT · Dimensional ETF Trust 0,71% 6 483 864 NS 30 de abril de 2026 N-PORT
AVMV · AMERICAN CENTURY ETF TRUST 0,66% 251 956 NS 31 de mayo de 2026 N-PORT
COWZ · Pacer Funds Trust 0,65% 7 904 043 NS 30 de abril de 2026 N-PORT
QQWZ · Pacer Funds Trust 0,65% 20 246 NS 30 de abril de 2026 N-PORT
CVY · Invesco Exchange-Traded Fund Trust 0,64% 48 660 SH 8 de agosto de 2026 Diario
AUSF · Global X Funds 0,55% 287 430 NS 31 de mayo de 2026 N-PORT
ITAN · EA Series Trust 0,51% 27 790 NS 29 de mayo de 2026 N-PORT
ABCS · EA Series Trust 0,50% 3 459 NS 29 de mayo de 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,44% 184 557 NS 30 de abril de 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,40% 117 672 NS 30 de abril de 2026 N-PORT
STNC · Hennessy Funds Trust 0,40% 24 403 NS 30 de abril de 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0,39% 16 955 526 SH 8 de agosto de 2026 Diario
AVLV · AMERICAN CENTURY ETF TRUST 0,37% 2 917 765 NS 31 de mayo de 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0,35% 10 400 000 8 de agosto de 2026 Diario
SCHM · SCHWAB STRATEGIC TRUST 0,35% 3 114 448 NS 31 de mayo de 2026 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,34% 466 740 NS 30 de abril de 2026 N-PORT
DFSV · Dimensional ETF Trust 0,33% 1 672 565 NS 30 de abril de 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0,31% 91 932 NS 30 de abril de 2026 N-PORT
IYH · iShares Trust 0,31% 697 150 SH 8 de agosto de 2026 Diario
VFVA · VANGUARD WELLINGTON FUND 0,28% 150 960 SH 8 de agosto de 2026 Diario
FHLC · FIDELITY COVINGTON TRUST 0,28% 530 957 NS 30 de abril de 2026 N-PORT
RXL · ProShares Trust 0,27% 12 010 NS 31 de mayo de 2026 N-PORT
AVMC · AMERICAN CENTURY ETF TRUST 0,27% 67 551 NS 31 de mayo de 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,27% 3 499 976 SH 8 de agosto de 2026 Diario
VFMF · VANGUARD WELLINGTON FUND 0,26% 115 598 SH 8 de agosto de 2026 Diario
REVS · Columbia ETF Trust I 0,26% 49 318 NS 30 de abril de 2026 N-PORT
ESML · iShares Trust 0,26% 454 086 SH 8 de agosto de 2026 Diario
IMCV · iShares Trust 0,25% 179 939 SH 8 de agosto de 2026 Diario
SMMD · iShares Trust 0,25% 581 770 SH 8 de agosto de 2026 Diario
CURE · Direxion Shares ETF Trust 0,25% 22 967 NS 30 de abril de 2026 N-PORT
IXJ · iShares Trust 0,24% 611 025 SH 8 de agosto de 2026 Diario
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0,23% 115 075 NS 30 de abril de 2026 N-PORT